Related Experiment Video
Updated: Jun 1, 2026
08:39
A Murine Model of Hemodialysis Access-Related Hand Dysfunction
Published on: May 31, 2022
Mesenchymal stem cell injection ameliorates chronic renal failure in a rat model
Sandra Villanueva1, Ernesto Ewertz, Flavio Carrión
1Laboratory of Integrative and Molecular Physiology, Los Andes University, Santiago, Chile. svillanueva@uandes.cl
Clinical Science (London, England : 1979)
|June 17, 2011
Summary
Mesenchymal stem cells (MSC) show promise in treating chronic kidney disease (CKD) by improving kidney function and reducing damage markers. This study demonstrates MSC therapy
Area of Science:
- Nephrology
- Regenerative Medicine
- Cell Therapy
Background:
- Chronic kidney disease (CKD) is a significant public health concern with limited therapeutic options for halting disease progression.
- Current treatments can reduce proteinuria but fail to prevent CKD advancement.
- Cell therapies, particularly those involving mesenchymal stem cells (MSC), are gaining attention for their regenerative potential in CKD.
Purpose of the Study:
- To investigate the therapeutic effects of MSC on the progression of chronic kidney disease (CKD) in a rat model.
- To assess the expression of molecular biomarkers associated with regenerative processes following MSC administration.
- To evaluate the impact of MSC on kidney function and structural damage markers.
Main Methods:
- An experimental model of 5/6 nephrectomy (NPX) induced CKD in adult male Sprague-Dawley rats.
- Intravenous administration of mesenchymal stem cells (MSC) or culture medium, with a sham group as control.
- Assessment of kidney function via plasma creatinine, and structural damage using H&E staining, ED-1, and α-SMA.
- Analysis of regenerative biomarkers including epitheliogenic (Pax-2, bFGF, BMP-7) and angiogenic (VEGF, Tie-2) proteins.
Main Results:
- Mesenchymal stem cells (MSC) were successfully detected in kidney tissues post-infusion.
- MSC treatment led to a significant reduction in plasma creatinine and damage markers (ED-1, α-SMA).
- A notable increase in the expression of regenerative proteins (epitheliogenic and angiogenic) was observed in MSC-treated rats, correlating with improved renal function.
Conclusions:
- Intravenous administration of mesenchymal stem cells (MSC) demonstrates a significant renoprotective effect in a rat model of chronic kidney disease (CKD).
- MSC therapy promotes kidney repair by reducing structural damage and enhancing the expression of key regenerative biomarkers.
- Further research is warranted to explore the safety, cost-effectiveness, and optimal dosing of MSC for clinical application in CKD treatment.
